Kontafarma China Holdings Limited

SEHK:1312 Stock Report

Market Cap: HK$150.9m

Kontafarma China Holdings Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Kontafarma China Holdings.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth11.1%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Is Kontafarma China Holdings (HKG:1312) Weighed On By Its Debt Load?

Dec 20
Is Kontafarma China Holdings (HKG:1312) Weighed On By Its Debt Load?

Kontafarma China Holdings Limited's (HKG:1312) Price Is Right But Growth Is Lacking After Shares Rocket 44%

Oct 09
Kontafarma China Holdings Limited's (HKG:1312) Price Is Right But Growth Is Lacking After Shares Rocket 44%

Is Kontafarma China Holdings (HKG:1312) Weighed On By Its Debt Load?

Sep 04
Is Kontafarma China Holdings (HKG:1312) Weighed On By Its Debt Load?

Here's Why Kontafarma China Holdings Limited's (HKG:1312) CEO Compensation Is The Least Of Shareholders Concerns

May 31
Here's Why Kontafarma China Holdings Limited's (HKG:1312) CEO Compensation Is The Least Of Shareholders Concerns

There's No Escaping Kontafarma China Holdings Limited's (HKG:1312) Muted Revenues Despite A 61% Share Price Rise

May 24
There's No Escaping Kontafarma China Holdings Limited's (HKG:1312) Muted Revenues Despite A 61% Share Price Rise

Health Check: How Prudently Does Kontafarma China Holdings (HKG:1312) Use Debt?

Dec 28
Health Check: How Prudently Does Kontafarma China Holdings (HKG:1312) Use Debt?

Is Kontafarma China Holdings (HKG:1312) Using Debt Sensibly?

Sep 01
Is Kontafarma China Holdings (HKG:1312) Using Debt Sensibly?

Is Kontafarma China Holdings (HKG:1312) Using Debt Sensibly?

Dec 29
Is Kontafarma China Holdings (HKG:1312) Using Debt Sensibly?

Health Check: How Prudently Does Tongfang Kontafarma Holdings (HKG:1312) Use Debt?

Sep 15
Health Check: How Prudently Does Tongfang Kontafarma Holdings (HKG:1312) Use Debt?

Tongfang Kontafarma Holdings (HKG:1312) Has Debt But No Earnings; Should You Worry?

Apr 20
Tongfang Kontafarma Holdings (HKG:1312) Has Debt But No Earnings; Should You Worry?

Is Tongfang Kontafarma Holdings (HKG:1312) A Risky Investment?

Nov 04
Is Tongfang Kontafarma Holdings (HKG:1312) A Risky Investment?

Tongfang Kontafarma Holdings' (HKG:1312) Shareholders Are Down 90% On Their Shares

Feb 18
Tongfang Kontafarma Holdings' (HKG:1312) Shareholders Are Down 90% On Their Shares

These 4 Measures Indicate That Tongfang Kontafarma Holdings (HKG:1312) Is Using Debt Extensively

Dec 07
These 4 Measures Indicate That Tongfang Kontafarma Holdings (HKG:1312) Is Using Debt Extensively

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Kontafarma China Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SEHK:1312 - Analysts future estimates and past financials data (HKD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/2024837-636280N/A
3/31/2024823-463859N/A
12/31/2023809-291337N/A
9/30/2023841-12N/AN/AN/A
6/30/20238745-2321N/A
3/31/2023884-40-389N/A
12/31/2022894-85-54-2N/A
9/30/2022997-24N/AN/AN/A
6/30/2022869-10-660N/A
3/31/2022836-29-1168N/A
12/31/2021803-48-1675N/A
6/30/2021938-119-18212N/A
3/31/2021974-81-78110N/A
12/31/20201,009-4226207N/A
6/30/202066166145228N/A
3/31/20207916043127N/A
12/31/201992154-5926N/A
9/30/20191,28029-672N/A
6/30/20191,6662247118N/A
3/31/20191,880272193N/A
12/31/20182,09432-567N/A
9/30/20181,98512-747N/A
6/30/20181,876-8-143-53N/A
3/31/20181,610-5N/A-50N/A
12/31/20171,344-2N/A-47N/A
9/30/20171,175-15N/A-68N/A
6/30/20171,006-27N/A-89N/A
3/31/2017820-32N/A-38N/A
12/31/2016633-37N/A12N/A
9/30/2016539-43N/A-16N/A
6/30/2016445-49N/A-43N/A
3/31/2016456-41N/A-72N/A
12/31/2015466-34N/A-100N/A
9/30/2015547-18N/A-36N/A
6/30/2015628-2N/A28N/A
3/31/20156818N/A10N/A
12/31/201473317N/A-8N/A
9/30/201474728N/A-40N/A
6/30/201476138N/A-72N/A
3/31/201473235N/A-68N/A
12/31/201370333N/A-64N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 1312's forecast earnings growth is above the savings rate (2.3%).

Earnings vs Market: Insufficient data to determine if 1312's earnings are forecast to grow faster than the Hong Kong market

High Growth Earnings: Insufficient data to determine if 1312's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 1312's revenue is forecast to grow faster than the Hong Kong market.

High Growth Revenue: Insufficient data to determine if 1312's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 1312's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 16:47
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Kontafarma China Holdings Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution